Structured. Defensible.
Transparent.
VativoRx delivers claim-level rebate management across pharmacy and medical — built for organizations that need more than visibility. They need a process that holds.
Pharmacy & Medical Rebate Management
VativoRx manages manufacturer rebates across both pharmacy and medical claims — with the same validation rigor applied to each. For most organizations, pharmacy is reasonably covered. Medical is where the gap is.
Schedule a Discovery Call →Where Opportunity Gets Lost
Pharmacy benefit rebates are contractually structured through PBM relationships and generally tracked at a detailed level. Most organizations have a reasonable handle on the pharmacy side. Medical-benefit rebates are a different picture. Drugs billed under the medical benefit — physician-administered therapies, specialty infusion, biologics outside the pharmacy channel — carry real rebate eligibility that most organizations are not capturing consistently. The eligibility rules are more complex, the vendor coverage is patchwork, and the reporting rarely arrives in a format finance can use without additional translation. VativoRx is built to close that gap — without requiring you to change what is already working on the pharmacy side.
One Process. Both Benefit Types.
VativoRx applies a consistent, claim-level validation process across both pharmacy and medical claims. The methodology does not change based on which side of the benefit a drug falls on — the same rigor, the same documentation, the same reporting structure applies to both. For organizations with pharmacy already covered, that means adding medical-benefit visibility without disrupting existing programs. For organizations starting from scratch on both sides, it means one process, one reporting framework, and one partner across the full rebate picture.
Built to Be Explained
Rebate Reporting & Transparency
Most rebate vendors give you one report. VativoRx delivers a structured reporting suite — monthly operational outputs, quarterly strategic reviews, and an advisory layer that goes beyond tracking what happened to informing what should happen next.
Schedule a Discovery Call →Why Reporting Breaks Down
When rebate reporting comes from multiple vendors in multiple formats, nobody has the full picture. Finance is reconciling one view, compliance is reviewing another, operations is working from a third. Beyond the fragmentation problem, most reporting only tells you what was submitted and what was received. It doesn't tell you what you're missing — or what a different formulary decision could mean for next quarter's rebate picture.
Structured Reporting Across All Stakeholders
VativoRx produces a defined reporting suite across every engagement — organized by cadence and audience so each stakeholder gets what they need without a custom request.
The Six Report Types
A structured summary of claims submitted during the review month — giving finance and operations teams a consistent, cycle-over-cycle view of submission activity. Supports month-end review without requiring a dive into individual claim detail.
A claim-level breakdown of monthly submission activity — including eligibility status, drug identifiers, and categorization detail. The supporting documentation behind the summary view, for teams that need to reconcile or trace at the individual claim level.
A structured review of rebate activity across the full quarter — consolidating submission volume, eligibility outcomes, and program performance into a single view. Designed for quarterly account review conversations with internal and client-facing stakeholders.
A forward-looking view of expected rebate activity for the coming quarter, based on current claim volume and program participation. Supports budget planning and financial forecasting without requiring close-cycle finalization.
A structured record of rebate payments received — organized by drug, program, and period. Provides the documentation needed to reconcile actual received amounts against submitted claims and estimated activity, and supports internal accounting close.
An advisory output that identifies alternative drug options for therapies that are not currently rebate-eligible — where clinically appropriate substitutes exist with manufacturer rebate programs. Helps organizations evaluate formulary and purchasing decisions through a rebate-visibility lens without compromising clinical appropriateness.
Compliance-Focused Validation
Most rebate programs validate at the program level. VativoRx validates at the claim level — so every eligibility determination has a documented reason behind it, not just a program flag.
Schedule a Discovery Call →Why Validation Matters
Rebate eligibility decisions made without a documented methodology create a quiet compliance risk. The risk isn't usually fraud — it's the inability to explain, consistently and specifically, why a claim was included or excluded when someone asks. That question comes from auditors. It comes from finance. It comes from boards. And when the answer requires reconstructing logic after the fact, confidence in the entire rebate program takes a hit.
Consistent, Traceable Eligibility Decisions
VativoRx applies a structured validation framework designed to produce decisions that hold up — not just at the moment of submission, but under internal or external review at any point after.
Audit Readiness
Three things make a validation process defensible: documented rules, consistent application, and traceable decisions. VativoRx builds all three in by default.
Documented Validation Logic
Criteria applied to each claim are defined before the review begins and available for review at any time. No reconstruction required.
Consistent Methodology
The same framework is applied across every claim, every cycle. Inconsistency in exclusion logic is one of the most common sources of compliance exposure.
Claim-Level Audit Trail
Every eligibility determination is logged at the individual claim level. The record exists before anyone asks for it.
Data Handling & Security
Data exchanged as part of the validation process is transmitted via encrypted, secure file transfer — aligned to HIPAA and HITECH requirements. No PHI is required for initial analysis. Where sensitive data is involved in later stages, handling follows a documented, compliance-reviewed protocol.